N/A
Manufactured by Amgen, Inc
146,341 FDA adverse event reports analyzed
Last updated: 2026-04-14
PEGFILGRASTIM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amgen, Inc. The most commonly reported adverse reactions for PEGFILGRASTIM include DEVICE ADHESION ISSUE, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS, UNINTENTIONAL MEDICAL DEVICE REMOVAL, DEVICE MALFUNCTION, DEVICE USE ERROR. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PEGFILGRASTIM.
Out of 96,810 classified reports for PEGFILGRASTIM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 146,341 FDA FAERS reports that mention PEGFILGRASTIM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEVICE ADHESION ISSUE, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS, UNINTENTIONAL MEDICAL DEVICE REMOVAL, DEVICE MALFUNCTION, DEVICE USE ERROR, DEVICE ISSUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amgen, Inc in connection with PEGFILGRASTIM. Always verify the specific product and NDC with your pharmacist.